Alle Storys
Folgen
Keine Story von ScheBo Biotech AG mehr verpassen.

ScheBo Biotech AG

The Forgotten Organ - Why to Screen for Exocrine Pancreatic Malfunction with respect to Diabetes Mellitus!
Tumour Metabolism - A Novel Concept Closes a Clinical Gap!

Giessen, Germany (ots)

Diabetes mellitus and cancer are among
the diseases of greatest clinical focus. At the ScheBo Biotech AG
Symposium during MEDICA on the occasion of the World Congress of
Pathology and Laboratory Medicine (WASPaLM) 2001 two specific
diagnostic tools with unique clinical approaches will be presented.
Since the availability of the ScheBo Pancreatic Elastase 1 stool
test, which fulfils all the criteria of a screening test, exocrine
pancreatic disturbances can be easily detected without stressing the
patient, leading to an appropriate treatment. Moreover, strong
evidence has shown that the endocrine pancreatic system (diabetes
mellitus) is very closely linked to the exocrine system, and they are
influenced by each other.
The decision of the right therapy is one of the major clinical
challenges in oncology. Looking for primary effects of carcinogenesis
will give additional information about the development of cancer at
an early stage ScheBo Tumor M2-PK detects a metabolic switch in
cancer cells reflecting the availability of new compounds necessary
for fast growth. This meaningful metabolic change is highly specific
for tumour cells and not observed in normal proliferating cells.
Thus, checking the metabolic state of cancer cells will be the future
tool of clinicians to assess the therapy and follow-up the patient. A
new concept in diagnosing and following-up patients approaches the
oncological clinic.
Topics are:
  • Pancreatic Elastase 1 - A Screening Marker for the Second Metabolic Syndrome in Patients with Diabetes Mellitus
  • A Unique Approach for Clinical Practice using the Tumor Metabolic Marker Tumor M2-PK
Venue: MEDICA Congress Centre (CCD South), Duesseldorf  Germany
   Date:  Thursday 22nd November 2001, 14:00 - 17:00
Please refer to our website for further information: www.schebo.com.
ots Original Text Service: ScheBo Biotech AG
Internet: http://www.presseportal.de

Contact:

Dr. Martin Schoendorf
Product Group Manager International
ScheBo Biotech AG
Netanyastrasse 3 - 5
D-35394 Giessen/ Germany
Tel.: +49-(0)641-4996-0
Fax: +49-(0)641-4996-77

Original-Content von: ScheBo Biotech AG, übermittelt durch news aktuell